IC100: a novel anti-ASC monoclonal antibody improves functional outcomes in an animal model of multiple sclerosis.

Haritha L DesuMelanie PlastiniPlacido IllianoHelen M BramlettW Dalton DietrichJuan Pablo de Rivero VaccariRoberta BrambillaRobert W Keane

Published in: Journal of neuroinflammation (2020)

These data indicate that IC100 suppresses the immune-inflammatory response that drives EAE development and progression, thereby identifying ASC as a promising target for the treatment of MS as well as other neurological diseases with a neuroinflammatory component.

Keyphrases

multiple sclerosis
monoclonal antibody
inflammatory response
nlrp inflammasome
mass spectrometry
white matter
electronic health record
lipopolysaccharide induced
toll like receptor
big data
immune response
brain injury